| David Alan Weinberg, MD | |
|
248 Pleasant St Ste 1600, Concord Eye Care, Concord, NH 03301-2588 | |
| (603) 224-2020 | |
| (603) 228-0248 |
| Full Name | David Alan Weinberg |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 40 Years |
| Location | 248 Pleasant St Ste 1600, Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164502076 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Concord Hospital | Concord, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Ophthalmologic Associates Pa | 0547250920 | 15 |
News Archive
MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).
Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
A woman successfully treated for a recurrent Clostridium difficile infection with stool from an overweight donor rapidly gained weight herself afterwards, becoming obese, according to a case report published in the new journal Open Forum Infectious Diseases.
Compliance with proposed emergency department length of stay measures for admitted, discharged, transferred, and observed patients does not differ significantly between safety-net hospitals (which serve higher proportion of patients with poorer health care status) and non-safety-net hospitals, addressing the issue of whether safety-net hospitals may not be able to meet certain performance measures and could be at risk of reduced funding, according to a study in the February 1 issue of JAMA.
› Verified 4 days ago
| Entity Name | Concord Ophthalmologic Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831183268 PECOS PAC ID: 0547250920 Enrollment ID: O20040517001006 |
News Archive
MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).
Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
A woman successfully treated for a recurrent Clostridium difficile infection with stool from an overweight donor rapidly gained weight herself afterwards, becoming obese, according to a case report published in the new journal Open Forum Infectious Diseases.
Compliance with proposed emergency department length of stay measures for admitted, discharged, transferred, and observed patients does not differ significantly between safety-net hospitals (which serve higher proportion of patients with poorer health care status) and non-safety-net hospitals, addressing the issue of whether safety-net hospitals may not be able to meet certain performance measures and could be at risk of reduced funding, according to a study in the February 1 issue of JAMA.
› Verified 4 days ago
| Entity Name | The Medical Eye Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225004955 PECOS PAC ID: 7315916095 Enrollment ID: O20040929000647 |
News Archive
MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).
Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
A woman successfully treated for a recurrent Clostridium difficile infection with stool from an overweight donor rapidly gained weight herself afterwards, becoming obese, according to a case report published in the new journal Open Forum Infectious Diseases.
Compliance with proposed emergency department length of stay measures for admitted, discharged, transferred, and observed patients does not differ significantly between safety-net hospitals (which serve higher proportion of patients with poorer health care status) and non-safety-net hospitals, addressing the issue of whether safety-net hospitals may not be able to meet certain performance measures and could be at risk of reduced funding, according to a study in the February 1 issue of JAMA.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Alan Weinberg, MD 248 Pleasant St Ste 1600, Concord Eye Care, Concord, NH 03301-2588 Ph: (603) 224-2020 | David Alan Weinberg, MD 248 Pleasant St Ste 1600, Concord Eye Care, Concord, NH 03301-2588 Ph: (603) 224-2020 |
News Archive
MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).
Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
A woman successfully treated for a recurrent Clostridium difficile infection with stool from an overweight donor rapidly gained weight herself afterwards, becoming obese, according to a case report published in the new journal Open Forum Infectious Diseases.
Compliance with proposed emergency department length of stay measures for admitted, discharged, transferred, and observed patients does not differ significantly between safety-net hospitals (which serve higher proportion of patients with poorer health care status) and non-safety-net hospitals, addressing the issue of whether safety-net hospitals may not be able to meet certain performance measures and could be at risk of reduced funding, according to a study in the February 1 issue of JAMA.
› Verified 4 days ago
Maynard B Wheeler, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 248 Pleasant Street, Suite 1600, Concord, NH 03301 Phone: 603-224-2020 Fax: 603-228-0248 | |
Maxwell Arrington Snead Iii, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2 Pillsbury St Ste 100, Concord, NH 03301 Phone: 603-228-1104 | |
Dr. Tighe Curtis Richardson, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2 Pillsbury St Ste 100, Concord, NH 03301 Phone: 603-224-2020 Fax: 603-228-7061 | |
Andre A D'hemecourt, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2 Pillsbury St Ste 100, Concord, NH 03301 Phone: 603-228-1104 Fax: 603-228-7061 | |
Christie L Morse, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 248 Pleasant St, Suite 1600, Concord, NH 03301 Phone: 603-224-2020 Fax: 603-228-0248 | |
Bradford S Hall, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 248 Pleasant St, Ste 1600, Concord, NH 03301 Phone: 603-224-2020 Fax: 603-228-0248 |